This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bulls Charging Into Mylan

By Mike Yamamoto of OptionMonster
NEW YORK -- Mylan (MYL) hit a new all-time high on Friday, and the bulls are looking for even more gains.
OptionMonster's tracking systems detected the purchase of more than 9,000 July 55 calls, mostly going for 88 cents to $1.09. This is clearly fresh buying, as the volume was far above the strike's  previous open interest of just 227 contracts.
These calls lock in the price where a stock can be bought through mid-July no matter how far it might climb, letting traders position for gains at a fraction of the cost with potentially significant leverage. The contracts could be sold earlier at a profit if premiums rise with a rally before then, but they will expire worthless if shares remain below $55.
The pharmaceutical name also drew bullish activity in the April 49 calls, with more than 1,700 purchased for $1.52 to $1.59 against open interest of 63 contracts.
Mylan's shares rose 1.93% to $45.97, just off their intraday peak of $46.01, and are up 63% in the last year. The company is scheduled to present at the J.P. Morgan Annual Healthcare Conference on Tuesday.
Overall option volume in Mylan was just shy of 20,500 contracts on Friday, more than 10 times its daily average for the last month. Calls accounted for more than 90% of the total, reflecting the session's bullish sentiment.
Yamamoto has no positions in MYL.

This commentary comes from an independent investor or market observer as part of TheStreet guest contributor program. The views expressed are those of the author and do not necessarily represent the views of TheStreet or its management.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.31 1.80%
FB $117.60 -0.82%
GOOG $695.17 -0.44%
TSLA $234.00 -3.20%
YHOO $36.18 -0.96%


Chart of I:DJI
DOW 17,771.66 -119.50 -0.67%
S&P 500 2,063.80 -17.63 -0.85%
NASDAQ 4,773.2230 -44.3710 -0.92%

Free Reports